Emmaus Life Sciences Files Q1 2025 10-Q

Ticker: EMMA · Form: 10-Q · Filed: May 15, 2025 · CIK: 822370

Sentiment: neutral

Topics: 10-Q, financials, related-party-transactions

TL;DR

Emmaus Life Sciences filed its Q1 2025 10-Q, showing financial details on related party notes and stockholder receivables.

AI Summary

Emmaus Life Sciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial items include details on promissory notes and convertible notes payable to related parties, as well as receivables from stockholders.

Why It Matters

This filing provides investors with the latest financial snapshot of Emmaus Life Sciences, Inc., crucial for understanding its current financial health and operational status.

Risk Assessment

Risk Level: medium — The filing contains details on related party transactions and receivables, which can sometimes indicate financial complexities or risks.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 15, 2025.

What is the Central Index Key (CIK) for Emmaus Life Sciences, Inc.?

The CIK for Emmaus Life Sciences, Inc. is 0000822370.

What are some of the financial items mentioned in relation to related parties?

The filing mentions 'PromissoryNotePayableAndConvertibleNotesPayableToRelatedParties' and 'NotesPayableToRelatedParties'.

What is the business address of Emmaus Life Sciences, Inc.?

The business address is 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA 90503.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Emmaus Life Sciences, Inc. (EMMA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing